Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2012

View Archived Issues

New PAK-4 inhibitor under development to treat gastric cancers

Scientists discover novel neurotrophic drug to treat cognitive decline

Findings presented from two phase III trials of Lu-AA-21004 in GAD

Kinetin shows promise to treat familial dysautonomia

Astellas Pharma presents new drug for treatment of transplant rejection

Toray divulges new inhibitors of 11-beta-HSD1

New camptothecin derivatives designed in Spain

IntraCellular Therapies claims novel phosphodiesterase 1B inhibitors

Novel phosphodiesterase inhibitors disclosed

New monoglyceride lipase inhibitors prepared by Sanofi

Syndax Pharmaceuticals designs new azacitidine prodrugs

Roche presents novel drugs for Parkinson's disease

FDA advisory committee to review Xgeva sBLA

Apricus Biosciences finalizes acquisition

BG Medicine files application for second cardiovascular diagnostic test

Marshall Edwards raises funds to advance lead oncology candidates

Opko Health completes acquisition

Symmetry Medical acquires surgical instruments business

Amgen moves AMG-172 to clinic

MethylGene recruiting participants in phase II MGCD-290 study

Gene therapy for wet AMD enters phase I/II testing

Clinical trial application submitted in Russia for AT-001

Clinical development ZP-1846 advances

FDA expands indication of Prevnar 13

Prima BioMed provides update on preclinical testing of Cripto-1 immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...